MPR Weekly Dose Podcast #120
FDA panel vote on COVID-19 vaccines for young children; new drug approved to treat alopecia; Paxlovid tested in standard risk individuals.
Alopecia
Olumiant Approved for Severe Alopecia Areata
The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata.
Significant Hair Regrowth Observed With Investigational JAK Inhibitor in Alopecia Areata Trial
The THRIVE-AA1 trial included adults aged 18 to 65 years with moderate to severe alopecia areata who had at least 50% scalp hair loss.
Treatments Explored for Moderate-to-Severe Alopecia Areata
Improvement in lesional scalp transcriptome toward nonlesional profile seen at week 24 for both ritlecitinib, brepocitinib
Taxane-Containing Chemo Associated With Persistent Alopecia
However, many patients experience improvements in hair density with standard alopecia treatments
Second Alopecia Areata Trial Demonstrates Hair Regrowth With Baricitinib
Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.
Baricitinib Improves Hair Regrowth in Alopecia Areata Trial
Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.
Disproportionality Signal Found for Suicidality in Finasteride Users
Younger patients and those with alopecia have significant disproportionality signals for increased suicidality
Investigational Oral JAK Inhibitor Gets Breakthrough Tx Status for Alopecia Areata
The FDA has granted Breakthrough Therapy designation to CTP-543 (Concert Pharmaceuticals), an oral Janus kinase (JAK) inhibitor for alopecia areata.
Baricitinib Receives Breakthrough Therapy Status for Alopecia Areata
The FDA has granted Breakthrough Therapy designation to baricitinib (LY3009104; Lilly), an oral Janus Kinase (JAK) inhibitor, for the treatment of alopecia areata.
